Cited by 2,066Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and ManagementSkin Diseases and Diabetes

Inflammation in obesity, diabetes, and related disorders

Open access
Rohm, Theresa V., Meier, Daniel T., Olefsky, Jerrold M., Donath, Marc Y.·2022·Immunity

Abstract

Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state contributes to long-term complications of diabetes, including non-alcoholic fatty liver disease (NAFLD), retinopathy, cardiovascular disease, and nephropathy, and may underlie the association of type 2 diabetes with other conditions such as Alzheimer's disease, polycystic ovarian syndrome, gout, and rheumatoid arthritis. Here, we review the current understanding of the mechanisms underlying inflammation in obesity, T2D, and related disorders. We discuss how chronic tissue inflammation results in IR, impaired insulin secretion, glucose intolerance, and T2D and review the effect of inflammation on diabetic complications and on the relationship between T2D and other pathologies. In this context, we discuss current therapeutic options for the treatment of metabolic disease, advances in the clinic and the potential of immune-modulatory approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.12.013

Cites

415 of 415 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Obesity amplifies systemic inflammation, creating a self-perpetuating cycle that increases risk of cardiovascular disease and diabetes.

    “Obesity further amplifies systemic inflammation, creating a self-perpetuating cycle that markedly increases the risk of cardiovascular disease and diabetes [38].”

    From Navigating the potential of algal peptides: health effects, market applications, and scientific challenges (2026) · cites this paper as [38]

    The Introduction sections on obesity and T2D and on cardiovascular disease link obesity-related inflammation to metabolic dysfunction and CVD. The source does not establish the claimed self-perpetuating cycle or characterize the increase in risk as marked; those parts go beyond the cited passages. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Inflammatory cytokines IL-1β and TNF-α, abundant in the AD brain, suppress GLUT expression, while oxidative stress further destabilizes and inactivates transporter proteins.

    “Furthermore, inflammatory cytokines such as IL-1β and tumor necrosis factor alpha (TNF-α), abundant in the AD brain, suppress GLUT expression, while oxidative stress further destabilizes and inactivates transporter proteins.”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [73]

    The “Inflammation and Alzheimer’s disease” section says IL-1β is elevated in AD patients’ brains and TNF-α is released by activated microglia. It discusses their effects on APP, Aβ and tau, but does not say they suppress GLUT expression. The searched passages also do not support oxidative stress destabilizing or inactivating transporter proteins; no page number is available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Inflammation is critically implicated in the pathogenesis and progression of numerous diseases.

    “Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases.”

    From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [5]

  • Our data using Cd68-eGFP mice support previous findings that obesity is associated with chronic inflammation, as we observed increased expression numbers of Cd68-eGFP+ cells throughout the mouse.

    “Our data using Cd68-eGFP mice support previous findings that obesity is associated with chronic inflammation37, as we observed increased expression numbers of Cd68-eGFP+ cells throughout the mouse.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

7 of the 422 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. Akshintala D, Chugh R, Amer F, and Cusi K (2000). Nonalcoholic Fatty Liver Disease: The Overlooked Complication of Type 2 Diabetes. In Endotext, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Stratakis CA, Trence DL, and Wilson DP, eds. (South Dartmouth (MA)). 31310460
  2. Ebstein W (1876). Zur Therapie des Diabetes Mellitus, insbesondere über die Anwendung des Salicylsauren Natron bei demselben. In Berliner Klinische Wochenschrift, pp. 337– 340.
  3. Klover PJ, Zimmers TA, Koniaris LG, and Mooney RA (2003b). Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52, 2784– 2789. 14578297
  4. Ying W, Lee YS, Dong Y, Seidman JS, Yang M, Isaac R, Seo JB, Yang BH, Wollam J, Riopel M, (2019). Expansion of Islet-Resident Macrophages Leads to Inflammation Affecting beta Cell Proliferation and Function in Obesity. Cell Metab 29, 457– 474 e455. 30595478 PMC6701710

Cited by

Sorted by citations

Authors
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y.
Affiliations
  • University of California San Diego (US)
  • University of Basel (CH)
Corresponding author
Donath, Marc Y.
Venue
Immunity
Publisher
Elsevier BV
Published
2022-01
Volume
55
Issue
1
Pages
31-55
ISSN
1074-7613 (ISSN-L)
OpenAlex
W4206799195
Cited by
2,066
References
422
Citations by year
2026: 450 · 2025: 649 · 2024: 512 · 2023: 345 · 2022: 108 · 2021: 1 · 2013: 1
FWCI
64.52
Type
journal article
Language
en
Open access
Locations
  • Immunity (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK063491, DK101395)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_200177)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
Keywords
obesity, type 2 diabetes, chronic inflammation, insulin resistance, beta-cell dysfunction, insulin secretion, impaired glucose tolerance, non-alcoholic fatty liver disease, diabetes complications, Alzheimer's disease, polycystic ovary syndrome, gout, rheumatoid arthritis, cardiovascular disease, kidney disease, retinopathy, immunomodulatory therapy, metabolic disease treatment
MeSH terms
Animals, Diabetes Mellitus, Type 2, Humans, Inflammation, Insulin Resistance, Obesity, Diabetes Complications, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review